Overview and Scope
A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus.
Sizing and Forecast
The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance,global health initiatives, patient preference for injectable therapies..
The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies.. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
Segmentation & Regional Insights
The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp
Major Driver Impacting Market Growth
The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward. Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does. High blood sugar is a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is used in diabetes to stimulate the body to produce more insulin, which helps to lower blood sugar levels, so the rising prevalence of diabetes will propel the market growth. For instance, in December 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, the global population living with diabetes is approximately 537 million adults and further it is projected to rise to 643 million by 2030. Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist market.
Key Industry Players
Major companies operating in the GLP-1 receptor agonist market are focused on developing sustained-release GLP-1 receptor agonists to gain a competitive edge in the market. Sustained-release GLP-1 receptor agonists (GLP-1RAs) are a type of medication that slowly releases GLP-1RA into the bloodstream over time, which allows for longer-lasting effects and less frequent injections compared to traditional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, launched Mounjaro 2.5 mg or 5 mg Ateos. It is the world’s first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both the GLP-1 and GIP receptors. The GLP-1 receptor is involved in regulating blood sugar levels, while the GIP receptor is involved in stimulating insulin secretion and reducing appetite.
The glp-1 receptor agonist market report table of contents includes:
1. Executive Summary
2. GLP-1 Receptor Agonist Market Characteristics
3. GLP-1 Receptor Agonist Market Trends And Strategies
4. GLP-1 Receptor Agonist Market – Macro Economic Scenario
5. Global GLP-1 Receptor Agonist Market Size and Growth
..
31. Global GLP-1 Receptor Agonist Market Competitive Benchmarking
32. Global GLP-1 Receptor Agonist Market Competitive Dashboard
33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market
34.GLP-1 Receptor Agonist Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
